A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate Versus Tenofovir Alafenamide

Overview

Journal J Int Assoc Provid AIDS Care

Publisher Sage Publications

Specialty Infectious Diseases

Date 2020 Apr 17

PMID 32295453

Citations 52

Authors

Chanie Wassner

Nicole Bradley

Yuman Lee

Affiliations

Soon will be listed here.

Abstract

HIV is a serious chronic medical condition. Significant improvements in antiretroviral therapy have led to a transformation in its management. No curative treatment is available for HIV, and lifelong therapy is required with a combination of agents to control viral replication and prevent complications. Some of the older agents are notorious for many side effects, making patient compliance difficult, which is critical to preventing HIV resistance. Tenofovir is one of the newer, more tolerable, nucleotide reverse transcriptase inhibitors on the market; is a mainstay of many antiretroviral therapy combinations; and is now available in 2 different formulations, tenofovir disoproxil fumarate (TDF) and, the more recent, tenofovir alafenamide (TAF). These 2 formulations have very different pharmacokinetics, which seem to affect their efficacy and safety. This manuscript provides insight into the history of TDF and TAF development, their unique pharmacokinetics and pharmacology, clinically important adverse effects, monitoring, interactions, resistance, review of clinical studies, and guideline recommendations and clinical applications for tenofovir's various indications.

Citing Articles

The Real-World Impact of Long-Acting Injectable Cabotegravir-Rilpivirine on Weight and Renal Function.

McNaboe L, Ayala A, Kostka J, Wakefield D, Chirch L Cureus. 2025; 17(2):e78384.

PMID: 40041628 PMC: 11879144. DOI: 10.7759/cureus.78384.

Evaluating the Efficacy of Repurposed Antiretrovirals in Hepatitis B Virus Treatment: A Narrative Review of the Pros and Cons.

Ugbaja S, Omerigwe S, Ndlovu S, Ngcobo M, Gqaleni N Int J Mol Sci. 2025; 26(3).

PMID: 39940695 PMC: 11817041. DOI: 10.3390/ijms26030925.

Application of a Physiologically Based Pharmacokinetic Approach to Predict Tenofovir Pharmacokinetics During Pregnancy.

Abduljalil K, De Sousa Mendes M, Salem F, Benaboud S, Gardner I AAPS J. 2025; 27(1):43.

PMID: 39939515 DOI: 10.1208/s12248-025-01031-y.

Chronic kidney disease among people living with HIV on TDF based regimen: A systematic review and meta-analysis.

Yazie T, Shiferaw W, Gebeyehu A, Teshome A, Addisu Z, Belete A PLoS One. 2025; 20(2):e0318068.

PMID: 39913460 PMC: 11801554. DOI: 10.1371/journal.pone.0318068.

Lower incidence of hepatocellular carcinoma with tenofovir alafenamide in chronic hepatitis B: Evidence from a large-scale cohort.

Yoo H, Kim J, Yoo J, Lee H, Kim S, Kim Y JHEP Rep. 2025; 7(2):101268.

PMID: 39867683 PMC: 11762169. DOI: 10.1016/j.jhepr.2024.101268.

References

Miller M, Margot N, Lu B, Zhong L, Chen S, Cheng A . Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis. 2004; 189(5):837-46. DOI: 10.1086/381784. View

Lee W, He G, Eisenberg E, Cihlar T, Swaminathan S, Mulato A . Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother. 2005; 49(5):1898-906. PMC: 1087627. DOI: 10.1128/AAC.49.5.1898-1906.2005. View

Kearney B, Flaherty J, Shah J . Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004; 43(9):595-612. DOI: 10.2165/00003088-200443090-00003. View

Orkin C, Molina J, Negredo E, Arribas J, Gathe J, Eron J . Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically.... Lancet HIV. 2017; 5(1):e23-e34. DOI: 10.1016/S2352-3018(17)30179-0. View

Miller M . K65R, TAMs and tenofovir. AIDS Rev. 2004; 6(1):22-33. View

Melikian G, Rhee S, Taylor J, Fessel W, Kaufman D, Towner W . Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility. Antimicrob Agents Chemother. 2012; 56(5):2305-13. PMC: 3346663. DOI: 10.1128/AAC.05487-11. View

Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann H . Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study. J Hepatol. 2016; 66(1):11-18. DOI: 10.1016/j.jhep.2016.08.008. View

Chan H, Fung S, Seto W, Chuang W, Chen C, Kim H . Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2017; 1(3):185-195. DOI: 10.1016/S2468-1253(16)30024-3. View

Durand-Gasselin L, Van Rompay K, Vela J, Henne I, Lee W, Rhodes G . Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys. Mol Pharm. 2009; 6(4):1145-51. PMC: 2777719. DOI: 10.1021/mp900036s. View

10.

Maenza J, Flexner C . Combination antiretroviral therapy for HIV infection. Am Fam Physician. 1998; 57(11):2789-98. View

11.

Wainberg M, Miller M, Quan Y, Salomon H, Mulato A, Lamy P . In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther. 2000; 4(2):87-94. DOI: 10.1177/135965359900400205. View

12.

Terrault N, Lok A, McMahon B, Chang K, Hwang J, Jonas M . Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018; 67(4):1560-1599. PMC: 5975958. DOI: 10.1002/hep.29800. View

13.

Birkus G, Kutty N, He G, Mulato A, Lee W, McDermott M . Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases. Mol Pharmacol. 2008; 74(1):92-100. DOI: 10.1124/mol.108.045526. View

14.

Fernandez-Fernandez B, Montoya-Ferrer A, Sanz A, Sanchez-Nino M, Izquierdo M, Poveda J . Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat. 2011; 2011:354908. PMC: 3119412. DOI: 10.1155/2011/354908. View

15.

Sax P, Wohl D, Yin M, Post F, DeJesus E, Saag M . Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015; 385(9987):2606-15. DOI: 10.1016/S0140-6736(15)60616-X. View

16.

Halegoua-De Marzio D, Hann H . Then and now: the progress in hepatitis B treatment over the past 20 years. World J Gastroenterol. 2014; 20(2):401-13. PMC: 3923015. DOI: 10.3748/wjg.v20.i2.401. View

17.

Callebaut C, Stepan G, Tian Y, Miller M . In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate. Antimicrob Agents Chemother. 2015; 59(10):5909-16. PMC: 4576064. DOI: 10.1128/AAC.01152-15. View

18.

van Bommel F, de Man R, Wedemeyer H, Deterding K, Petersen J, Buggisch P . Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology. 2009; 51(1):73-80. DOI: 10.1002/hep.23246. View

19.

Ray A, Fordyce M, Hitchcock M . Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus. Antiviral Res. 2015; 125:63-70. DOI: 10.1016/j.antiviral.2015.11.009. View

20.

Sluis-Cremer N, Sheen C, Zelina S, Torres P, Parikh U, Mellors J . Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2006; 51(1):48-53. PMC: 1797654. DOI: 10.1128/AAC.00683-06. View